Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study

Journal of Thoracic Disease

article

Haiyu Zhou¹  Lili Lin³  Tao Qin³  Wei Ren³  Yujie Tan³  Qiong Yang³  Huixin Xu³  Xinxin Xie³  Yongjian Chen⁴  Shengbo Liu¹  Xing Li⁴  Zhihua Li³  Hai Hu³  Yunfang Yu³  Herui Yao³ 

[1] Division of Thoracic Surgery, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology;Division of Thoracic Surgery, Jiangxi Lung Cancer Institute, Jiangxi Provincial Cancer Hospital;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital of Sun Yat-sen University;Department of Medical Oncology, Third Affiliated Hospital of Sun Yat-sen University;AI & Digital Media Concentration Program, Division of Science and Technology, Beijing Normal University-Hong Kong Baptist University United International College

关键词: Neoadjuvant therapy;    non-small cell lung cancer (NSCLC);    immune;    checkpoint inhibitors;    artificial intelligence;    major pathological response;   

DOI  :  10.21037/jtd-21-1022

学科分类：呼吸医学

来源: Pioneer Bioscience Publishing Company

【 摘 要 】

Background: Previous studies have shown that neoadjuvant immune checkpoint inhibitors (ICIs) combined with chemotherapy in patients with stage IB–IIIA non-small cell lung cancer (NSCLC) significantly improved the major pathological response (MPR) and the pathological complete response (pCR) rates. However, high-level evidence-based medical data confirming this effect are still lacking. In addition, there is an urgent need to develop an appropriate strategy to predict the benefit for patients receiving ICIs. In this study, we describe an ongoing study on the effect of neoadjuvant therapy with camrelizumab, nab-paclitaxel, and carboplatin on stage IB–IIIA NSCLC patients. The aim of this study is to establish a multiomics artificial intelligence system for predicting neoadjuvant therapy efficacy and assisting decision-making. Methods: This prospective, single-arm, multicenter, phase II trial will enroll a total of 40 patients who will undergo surgery after three cycles of neoadjuvant therapy with camrelizumab, nab-paclitaxel, and carboplatin. The MPR rate is the primary endpoint, while the rates of pCR, complete resection, objective response, disease-free survival (DFS), adverse events (AEs), and quality of life (QOL) are secondary endpoints. Exploratory endpoints will serve to establish a multiomics artificial intelligence system for neoadjuvant therapy effect prediction and decision-making assistance based on radiomics, metabolism, genetic, and clinic-pathological characteristics and to explore the mechanisms of drug resistance. Discussion: The efficacy of ICIs is influenced by many factors, including patient’s driver genes and smoking status. Thus, further subgroup analysis is needed. This study will indicate if our new multiomics artificial intelligence system constitutes a valid strategy for neoadjuvant therapy effect prediction and decision-making assistance in the context of neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin treatment for patients with stage IB–IIIA NSCLC. Trial Registration: This trial has been registered at ClinicalTrials.gov (identification number: NCT04541251).

【 授权许可】

Unknown